ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 661

ASDAS Can be Reliably Calculated When Only the Patient’s Overall Basdai Score Is Available, but Not the Score(S) of Its Individual Component(S)

Pinar Cetin1, Gokce Kenar1, Sedat Capar2, Handan Yarkan1, Berrin Zengin1, Ismail Sari1, Merih Birlik1, Fatos Onen1 and Nurullah Akkoc3, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 2Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, 3Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity and ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: ASDAS is a composite measure of disease activity for ankylosing spondylitis (AS). Its calculation includes three BASDAI questions, BASDAI Q2 (back pain), Q3 (peripheral pain/swelling), and Q6 (morning stiffness), plus ESR or CRP, depending on the version. In many patients’ clinical records, BASDAI total score is included but the scores of its individual components are missing. Our aim was to assess the validity of imputing missing BASDAI items from the overall BASDAI score in order to calculate the patient’s ASDAS in such a clinical situation.

Methods: Patients with complete baseline data for ASDAS and BASDAI components were identified from our local AS database. Original ASDAS calculations were repeated by replacing each or all of the BASDAI items included in the formula with the overall BASDAI score. Kappa statistics was used to assess the agreement between the original and the imputed ASDAS scores, in classifying patients into different disease activity states (inactive, moderate, high and very high). The mean difference between scores was calculated. The analysis was completed with the Bland–Altman method.

Results: 403 patients with AS (age 44.4±11.8 years; 73.7% males) with a mean disease duration of 9.7±8.1 years were included in this analysis. Their mean (SD) BASDAI, ASDAS-CRP and ASDAS-ESR scores were 3.6 (2.3), 3.1 (1.1), and 3.1 (1.1), respectively. Kappa values ranged from 0.80 to 0.89 (weighted kappa values from 0.84 to 0.96), with lower limits of the 95%CI all over 0.75 in the different imputation schemes (Table 1). The largest mean difference between the original and the imputed scores was 0.17.

Conclusion: The close agreement between the original and the imputed ASDAS scores observed in this analysis support the validity of imputing missing BASDAI items from the overall BASDAI, when the score(s) of its individual component(s) are lacking.

Table 1. Agreement between the original ASDAS and imputed scores after replacing individual BASDAI item values with overall BASDAI scores

Agreement level between the methods

Limits of agreement between the methods*

Kappa value

95% CI

Mean difference

Lower limit

Upper limit

ASDAS CRP vs ASDAS CRP imputed for three BASDAI items

0.8

0.74 to 0.85

0.07

−0.4

0.53

ASDAS CRP vs ASDAS CRP imputed for BASDAI item 2

0.8

0.75 to 0.85

0.17

−0.25

0.59

ASDAS CRP vs ASDAS CRP imputed for BASDAI item 3

0.88

0.84 to 0.92

−0.09

−0.38

0.2

ASDAS CRP vs ASDAS CRP imputed for BASDAI item 6

0.83

0.78 to 0.88

−0.02

−0.02

0.26

ASDAS ESR vs ASDAS ESR imputed for three BASDAI items

0.88

0.84 to 0.92

−0.02

−0.47

0.43

ASDAS ESR vs ASDAS ESR imputed for BASDAI item 2

0.89

0.85 to 0.93

0.12

−0.16

0.4

ASDAS ESR vs ASDAS ESR imputed for BASDAI item 3

0.82

0.78 to 0.88

−0.12

−0.49

0.26

ASDAS ESR vs ASDAS ESR imputed for BASDAI item 6

0.88

0.84 to 0.93

−0.02

−0.34

0.31


Disclosure: P. Cetin, None; G. Kenar, None; S. Capar, None; H. Yarkan, None; B. Zengin, None; I. Sari, None; M. Birlik, None; F. Onen, None; N. Akkoc, None.

To cite this abstract in AMA style:

Cetin P, Kenar G, Capar S, Yarkan H, Zengin B, Sari I, Birlik M, Onen F, Akkoc N. ASDAS Can be Reliably Calculated When Only the Patient’s Overall Basdai Score Is Available, but Not the Score(S) of Its Individual Component(S) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/asdas-can-be-reliably-calculated-when-only-the-patients-overall-basdai-score-is-available-but-not-the-scores-of-its-individual-components/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/asdas-can-be-reliably-calculated-when-only-the-patients-overall-basdai-score-is-available-but-not-the-scores-of-its-individual-components/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology